Former Seagen CEO Siegall Takes Helm At New Biotech Morphimmune
A Novel Targeted Oncology Platform
Executive Summary
Siegall is moving on after an unhappy exit from Seagen with a new role at another company with a novel targeted oncology platform.
You may also be interested in...
Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs
Pfizer expects its acquisition of Seagen to result in $10bn in new revenue by 2030 as the big pharma applies its resources to the target company’s pioneering antibody-drug conjugate technology.
Novartis Tunes Into Radiopharmaceuticals With Endocyte Buy
Endocyte paid just $12m upfront a year ago for a potential first-in-class investigational radioligand therapy for prostate cancer. Novartis is buying Endocyte for a whopping $2.1bn., highlighting the company's emphasis on building in radiopharmaceuticals.
Vertex’s Sickle Cell Treatment Gets December Decision Date, On Track To Be First CRISPR Therapy
Vertex now looks likely to gain US approval for the first ever CRISPR gene edited therapy by the end of the year, but could face immediate competition from Bluebird Bio.